Skip Navigation


Bioinformatics Advance Access originally published online on December 8, 2005
Bioinformatics 2006 22(4):466-471; doi:10.1093/bioinformatics/bti824
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (Print PDF) Freely available
Right arrow All Versions of this Article:
22/4/466    most recent
bti824v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Li, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information

Lexin Li

Department of Statistics, North Carolina State University Raleigh, NC 27695, USA

Motivation: It is important to predict the outcome of patients with diffuse large-B-cell lymphoma after chemotherapy, since the survival rate after treatment of this common lymphoma disease is <50%. Both clinically based outcome predictors and the gene expression-based molecular factors have been proposed independently in disease prognosis. However combining the high-dimensional genomic data and the clinically relevant information to predict disease outcome is challenging.

Results: We describe an integrated clinicogenomic modeling approach that combines gene expression profiles and the clinically based International Prognostic Index (IPI) for personalized prediction in disease outcome. Dimension reduction methods are proposed to produce linear combinations of gene expressions, while taking into account clinical IPI information. The extracted summary measures capture all the regression information of the censored survival phenotype given both genomic and clinical data, and are employed as covariates in the subsequent survival model formulation. A case study of diffuse large-B-cell lymphoma data, as well as Monte Carlo simulations, both demonstrate that the proposed integrative modeling improves the prediction accuracy, delivering predictions more accurate than those achieved by using either clinical data or molecular predictors alone.

Availability: R programs are available at http://www4.stat.ncsu.edu/~li/survipi/

Contact: li{at}stat.ncsu.edu

Supplementary information: Supplementary data are available at http://www4.stat.ncsu.edu/~li/survipi/bioinfo-supp.pdf

Received on July 14, 2005; revised on November 7, 2005; accepted on December 6, 2005

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. A. Anderson, R. M. Pfeiffer, J. S. Rapkin, G. Gridley, L. Mellemkjaer, K. Hemminki, M. Bjorkholm, N. E. Caporaso, and O. Landgren
Survival Patterns Among Lymphoma Patients With a Family History of Lymphoma
J. Clin. Oncol., October 20, 2008; 26(30): 4958 - 4965.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
J. Beane, P. Sebastiani, T. H. Whitfield, K. Steiling, Y.-M. Dumas, M. E. Lenburg, and A. Spira
A Prediction Model for Lung Cancer Diagnosis that Integrates Genomic and Clinical Features
Cancer Prevention Research, June 1, 2008; 1(1): 56 - 64.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Schramm, J. Vandesompele, J. H. Schulte, S. Dreesmann, L. Kaderali, B. Brors, R. Eils, F. Speleman, and A. Eggert
Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome
Clin. Cancer Res., March 1, 2007; 13(5): 1459 - 1465.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.